NCT00481455View on ClinicalTrials.gov

Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

September 30, 2007

Study Completion Date

October 31, 2008

Conditions
Recurrent Glioblastoma Multiforme
Interventions
DRUG

Panzem NCD

2000 mg q8h, continuous dosing in 28 day cycles

DRUG

Temozolomide

Fixed dose

Trial Locations (1)

27710

The Brain Tumor Center, Duke University Medical Center, Durham

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY